Abeona therapeutics submits biologics license application to u.s. fda seeking priority review and approval of eb-101 for the treatment of patients with recessive dystrophic epidermolysis bullosa

Cleveland, sept. 26, 2023 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today announced the company has submitted a biologics license application (bla) to the u.s. food and drug administration (fda) seeking approval of eb-101, its investigational autologous, engineered cell therapy, as a treatment for patients with recessive dystrophic epidermolysis bullosa (rdeb). as part of the submission, abeona requested a priority review, which, if granted, would shorten the fda's review period to six months from the filing acceptance of the bla, instead of 10 months under standard review.
ABEO Ratings Summary
ABEO Quant Ranking